Patents by Inventor Kelly Frye

Kelly Frye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20230374108
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: June 29, 2023
    Publication date: November 23, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • Citrate buffered VEGF antagonist formulations
    Patent number: 11806398
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: November 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11732024
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: August 22, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF Antagonist Formulations
    Publication number: 20210393530
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 7, 2021
    Publication date: December 23, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF Antagonist Formulations
    Publication number: 20210393778
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 6, 2021
    Publication date: December 23, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20210340220
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: June 15, 2021
    Publication date: November 4, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF Antagonist Formulations
    Publication number: 20210252105
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 5, 2021
    Publication date: August 19, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF Antagonist Formulations
    Publication number: 20210252147
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 4, 2021
    Publication date: August 19, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11084865
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: August 10, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11066458
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 20, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF Antagonist Formulations
    Publication number: 20210077624
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 18, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • Formulations of VEG antagonist fusion proteins and method of manufacturing them
    Patent number: 10857231
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: December 8, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20200131246
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 30, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20200017572
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 16, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS
    Publication number: 20190388539
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: August 8, 2019
    Publication date: December 26, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 10464992
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO: 4.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 5, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Method of manufacturing VEGF antagonist fusion proteins
    Patent number: 10406226
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: September 10, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 10400025
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: September 3, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20190031735
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO: 4.
    Type: Application
    Filed: October 12, 2018
    Publication date: January 31, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20180155408
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: January 24, 2018
    Publication date: June 7, 2018
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE